TY - JOUR
T1 - Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
AU - Borthakur, Gautam
AU - Cortes, Jorge E.
AU - Estey, Elihu E.
AU - Jabbour, Elias
AU - Faderl, Stefan
AU - O'Brien, Susan
AU - Garcia-Manero, Guillermo
AU - Kadia, Tapan Mahendra
AU - Wang, Xuemei
AU - Patel, Keyur
AU - Luthra, Rajyalakshmi
AU - Koller, Charles
AU - Brandt, Mark
AU - Ravandi, Farhad
AU - Kantarjian, Hagop
N1 - Publisher Copyright:
© 2014 Wiley Periodicals, Inc.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
AB - Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
UR - http://www.scopus.com/inward/record.url?scp=84908053861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908053861&partnerID=8YFLogxK
U2 - 10.1002/ajh.23795
DO - 10.1002/ajh.23795
M3 - Article
C2 - 24990142
AN - SCOPUS:84908053861
SN - 0361-8609
VL - 89
SP - 964
EP - 968
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 10
ER -